Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 161

1.

Characterization of transcriptomic signature of primary prostate cancer analogous to prostatic small cell neuroendocrine carcinoma.

Alshalalfa M, Liu Y, Wyatt AW, Gibb EA, Tsai HK, Erho N, Lehrer J, Takhar M, Ramnarine VR, Collins CC, Den RB, Schaeffer EM, Davicioni E, Lotan TL, Bismar TA.

Int J Cancer. 2019 May 24. doi: 10.1002/ijc.32430. [Epub ahead of print]

PMID:
31125117
2.

Upregulation of Scavenger receptor B1 is required for steroidogenic and non-steroidogenic cholesterol metabolism in prostate cancer.

Gordon JA, Noble JW, Midha A, Derakhshan F, Wang G, Adomat HH, Tomlinson Guns ES, Lin YY, Ren S, Collins CC, Nelson PS, Morrisey C, Wasan KM, Cox ME.

Cancer Res. 2019 May 7. pii: canres.2529.2018. doi: 10.1158/0008-5472.CAN-18-2529. [Epub ahead of print]

PMID:
31064850
3.

Combinatorial Detection of Conserved Alteration Patterns for Identifying Cancer Subnetworks.

Hodzic E, Shrestha R, Zhu K, Cheng K, Collins CC, Cenk Sahinalp S.

Gigascience. 2019 Apr 1;8(4). pii: giz024. doi: 10.1093/gigascience/giz024.

4.

The Proteogenomic Landscape of Curable Prostate Cancer.

Sinha A, Huang V, Livingstone J, Wang J, Fox NS, Kurganovs N, Ignatchenko V, Fritsch K, Donmez N, Heisler LE, Shiah YJ, Yao CQ, Alfaro JA, Volik S, Lapuk A, Fraser M, Kron K, Murison A, Lupien M, Sahinalp C, Collins CC, Tetu B, Masoomian M, Berman DM, van der Kwast T, Bristow RG, Kislinger T, Boutros PC.

Cancer Cell. 2019 Mar 18;35(3):414-427.e6. doi: 10.1016/j.ccell.2019.02.005.

PMID:
30889379
5.

BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma.

Shrestha R, Nabavi N, Lin YY, Mo F, Anderson S, Volik S, Adomat HH, Lin D, Xue H, Dong X, Shukin R, Bell RH, McConeghy B, Haegert A, Brahmbhatt S, Li E, Oo HZ, Hurtado-Coll A, Fazli L, Zhou J, McConnell Y, McCart A, Lowy A, Morin GB, Chen T, Daugaard M, Sahinalp SC, Hach F, Le Bihan S, Gleave ME, Wang Y, Churg A, Collins CC.

Genome Med. 2019 Feb 18;11(1):8. doi: 10.1186/s13073-019-0620-3.

6.

Metagenomic and metatranscriptomic analysis of human prostate microbiota from patients with prostate cancer.

Feng Y, Ramnarine VR, Bell R, Volik S, Davicioni E, Hayes VM, Ren S, Collins CC.

BMC Genomics. 2019 Feb 18;20(1):146. doi: 10.1186/s12864-019-5457-z.

7.

The long noncoding RNA HORAS5 mediates castration-resistant prostate cancer survival by activating the androgen receptor transcriptional program.

Parolia A, Venalainen E, Xue H, Mather R, Lin D, Wu R, Pucci P, Rogalski J, Evans JR, Feng F, Collins CC, Wang Y, Crea F.

Mol Oncol. 2019 May;13(5):1121-1136. doi: 10.1002/1878-0261.12471. Epub 2019 Mar 5.

8.

Structural variation and fusion detection using targeted sequencing data from circulating cell free DNA.

Gawroński AR, Lin YY, McConeghy B, LeBihan S, Asghari H, Koçkan C, Orabi B, Adra N, Pili R, Collins CC, Sahinalp SC, Hach F.

Nucleic Acids Res. 2019 Apr 23;47(7):e38. doi: 10.1093/nar/gkz067.

9.

Markers of MEK inhibitor resistance in low-grade serous ovarian cancer: EGFR is a potential therapeutic target.

Fernandez ML, Dawson A, Hoenisch J, Kim H, Bamford S, Salamanca C, DiMattia G, Shepherd T, Cremona M, Hennessy B, Anderson S, Volik S, Collins CC, Huntsman DG, Carey MS.

Cancer Cell Int. 2019 Jan 8;19:10. doi: 10.1186/s12935-019-0725-1. eCollection 2019.

10.

Alignment-free clustering of UMI tagged DNA molecules.

Orabi B, Erhan E, McConeghy B, Volik SV, Le Bihan S, Bell R, Collins CC, Chauve C, Hach F.

Bioinformatics. 2019 Jun 1;35(11):1829-1836. doi: 10.1093/bioinformatics/bty888.

PMID:
30351359
11.

Proteogenomic Characterization of Patient-Derived Xenografts Highlights the Role of REST in Neuroendocrine Differentiation of Castration-Resistant Prostate Cancer.

Flores-Morales A, Bergmann TB, Lavallee C, Batth TS, Lin D, Lerdrup M, Friis S, Bartels A, Kristensen G, Krzyzanowska A, Xue H, Fazli L, Hansen KH, Røder MA, Brasso K, Moreira JM, Bjartell A, Wang Y, Olsen JV, Collins CC, Iglesias-Gato D.

Clin Cancer Res. 2019 Jan 15;25(2):595-608. doi: 10.1158/1078-0432.CCR-18-0729. Epub 2018 Oct 1.

PMID:
30274982
12.

Pre-clinical Models for Malignant Mesothelioma Research: From Chemical-Induced to Patient-Derived Cancer Xenografts.

Nabavi N, Wei J, Lin D, Collins CC, Gout PW, Wang Y.

Front Genet. 2018 Jul 4;9:232. doi: 10.3389/fgene.2018.00232. eCollection 2018. Review.

13.

Targeting MCT4 to reduce lactic acid secretion and glycolysis for treatment of neuroendocrine prostate cancer.

Choi SYC, Ettinger SL, Lin D, Xue H, Ci X, Nabavi N, Bell RH, Mo F, Gout PW, Fleshner NE, Gleave ME, Collins CC, Wang Y.

Cancer Med. 2018 Jun 14. doi: 10.1002/cam4.1587. [Epub ahead of print]

14.

The long noncoding RNA landscape of neuroendocrine prostate cancer and its clinical implications.

Ramnarine VR, Alshalalfa M, Mo F, Nabavi N, Erho N, Takhar M, Shukin R, Brahmbhatt S, Gawronski A, Kobelev M, Nouri M, Lin D, Tsai H, Lotan TL, Karnes RJ, Rubin MA, Zoubeidi A, Gleave ME, Sahinalp C, Wyatt AW, Volik SV, Beltran H, Davicioni E, Wang Y, Collins CC.

Gigascience. 2018 Jun 1;7(6). doi: 10.1093/gigascience/giy050.

15.

MechRNA: prediction of lncRNA mechanisms from RNA-RNA and RNA-protein interactions.

Gawronski AR, Uhl M, Zhang Y, Lin YY, Niknafs YS, Ramnarine VR, Malik R, Feng F, Chinnaiyan AM, Collins CC, Sahinalp SC, Backofen R.

Bioinformatics. 2018 Sep 15;34(18):3101-3110. doi: 10.1093/bioinformatics/bty208.

16.

Heterochromatin Protein 1α Mediates Development and Aggressiveness of Neuroendocrine Prostate Cancer.

Ci X, Hao J, Dong X, Choi SY, Xue H, Wu R, Qu S, Gout PW, Zhang F, Haegert AM, Fazli L, Crea F, Ong CJ, Zoubeidi A, He HH, Gleave ME, Collins CC, Lin D, Wang Y.

Cancer Res. 2018 May 15;78(10):2691-2704. doi: 10.1158/0008-5472.CAN-17-3677. Epub 2018 Feb 27.

17.

Aneustat (OMN54) has aerobic glycolysis-inhibitory activity and also immunomodulatory activity as indicated by a first-generation PDX prostate cancer model.

Qu S, Xue H, Dong X, Lin D, Wu R, Nabavi N, Collins CC, Gleave ME, Gout PW, Wang Y.

Int J Cancer. 2018 Jul 15;143(2):419-429. doi: 10.1002/ijc.31310. Epub 2018 Mar 1.

18.

Treatment with docetaxel in combination with Aneustat leads to potent inhibition of metastasis in a patient-derived xenograft model of advanced prostate cancer.

Qu S, Ci X, Xue H, Dong X, Hao J, Lin D, Clermont PL, Wu R, Collins CC, Gout PW, Wang Y.

Br J Cancer. 2018 Mar 20;118(6):802-812. doi: 10.1038/bjc.2017.474. Epub 2018 Jan 30.

19.

Computational identification of micro-structural variations and their proteogenomic consequences in cancer.

Lin YY, Gawronski A, Hach F, Li S, Numanagic I, Sarrafi I, Mishra S, McPherson A, Collins CC, Radovich M, Tang H, Sahinalp SC.

Bioinformatics. 2018 May 15;34(10):1672-1681. doi: 10.1093/bioinformatics/btx807.

20.

Enzalutamide inhibits testosterone-induced growth of human prostate cancer xenografts in zebrafish and can induce bradycardia.

Melong N, Steele S, MacDonald M, Holly A, Collins CC, Zoubeidi A, Berman JN, Dellaire G.

Sci Rep. 2017 Oct 31;7(1):14698. doi: 10.1038/s41598-017-14413-w.

21.

Mutational Analysis of Gene Fusions Predicts Novel MHC Class I-Restricted T-Cell Epitopes and Immune Signatures in a Subset of Prostate Cancer.

Kalina JL, Neilson DS, Lin YY, Hamilton PT, Comber AP, Loy EMH, Sahinalp SC, Collins CC, Hach F, Lum JJ.

Clin Cancer Res. 2017 Dec 15;23(24):7596-7607. doi: 10.1158/1078-0432.CCR-17-0618. Epub 2017 Sep 27.

22.

Paid sick leave and psychological distress: An analysis of U.S. workers.

Stoddard-Dare P, DeRigne L, Collins CC, Quinn LM, Fuller K.

Am J Orthopsychiatry. 2018;88(1):1-9. doi: 10.1037/ort0000293. Epub 2017 Sep 14.

PMID:
28910124
23.

A germline FANCA alteration that is associated with increased sensitivity to DNA damaging agents.

Wilkes DC, Sailer V, Xue H, Cheng H, Collins CC, Gleave M, Wang Y, Demichelis F, Beltran H, Rubin MA, Rickman DS.

Cold Spring Harb Mol Case Stud. 2017 Sep;3(5). pii: a001487. doi: 10.1101/mcs.a001487. Epub 2017 May 3.

24.

Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation Therapy.

Beltran H, Wyatt AW, Chedgy EC, Donoghue A, Annala M, Warner EW, Beja K, Sigouros M, Mo F, Fazli L, Collins CC, Eastham J, Morris M, Taplin ME, Sboner A, Halabi S, Gleave ME.

Clin Cancer Res. 2017 Nov 15;23(22):6802-6811. doi: 10.1158/1078-0432.CCR-17-1034. Epub 2017 Aug 25.

25.

HIT'nDRIVE: patient-specific multidriver gene prioritization for precision oncology.

Shrestha R, Hodzic E, Sauerwald T, Dao P, Wang K, Yeung J, Anderson S, Vandin F, Haffari G, Collins CC, Sahinalp SC.

Genome Res. 2017 Sep;27(9):1573-1588. doi: 10.1101/gr.221218.117. Epub 2017 Jul 18.

26.

Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder Cancer.

Vandekerkhove G, Todenhöfer T, Annala M, Struss WJ, Wong A, Beja K, Ritch E, Brahmbhatt S, Volik SV, Hennenlotter J, Nykter M, Chi KN, North S, Stenzl A, Collins CC, Eigl BJ, Black PC, Wyatt AW.

Clin Cancer Res. 2017 Nov 1;23(21):6487-6497. doi: 10.1158/1078-0432.CCR-17-1140. Epub 2017 Jul 31.

27.

Metabolic heterogeneity signature of primary treatment-naïve prostate cancer.

Lin D, Ettinger SL, Qu S, Xue H, Nabavi N, Choi SYC, Bell RH, Mo F, Haegert AM, Gout PW, Fleshner N, Gleave ME, Pollak M, Collins CC, Wang Y.

Oncotarget. 2017 Apr 18;8(16):25928-25941. doi: 10.18632/oncotarget.15237.

28.

Alternative RNA splicing of the MEAF6 gene facilitates neuroendocrine prostate cancer progression.

Lee AR, Li Y, Xie N, Gleave ME, Cox ME, Collins CC, Dong X.

Oncotarget. 2017 Apr 25;8(17):27966-27975. doi: 10.18632/oncotarget.15854.

29.

Stromal Gene Expression is Predictive for Metastatic Primary Prostate Cancer.

Mo F, Lin D, Takhar M, Ramnarine VR, Dong X, Bell RH, Volik SV, Wang K, Xue H, Wang Y, Haegert A, Anderson S, Brahmbhatt S, Erho N, Wang X, Gout PW, Morris J, Karnes RJ, Den RB, Klein EA, Schaeffer EM, Ross A, Ren S, Sahinalp SC, Li Y, Xu X, Wang J, Wang J, Gleave ME, Davicioni E, Sun Y, Wang Y, Collins CC.

Eur Urol. 2018 Apr;73(4):524-532. doi: 10.1016/j.eururo.2017.02.038. Epub 2017 Mar 19.

PMID:
28330676
30.

Switching off malignant mesothelioma: exploiting the hypoxic microenvironment.

Nabavi N, Bennewith KL, Churg A, Wang Y, Collins CC, Mutti L.

Genes Cancer. 2016 Nov;7(11-12):340-354. doi: 10.18632/genesandcancer.124. Review.

31.

Genomic hallmarks of localized, non-indolent prostate cancer.

Fraser M, Sabelnykova VY, Yamaguchi TN, Heisler LE, Livingstone J, Huang V, Shiah YJ, Yousif F, Lin X, Masella AP, Fox NS, Xie M, Prokopec SD, Berlin A, Lalonde E, Ahmed M, Trudel D, Luo X, Beck TA, Meng A, Zhang J, D'Costa A, Denroche RE, Kong H, Espiritu SM, Chua ML, Wong A, Chong T, Sam M, Johns J, Timms L, Buchner NB, Orain M, Picard V, Hovington H, Murison A, Kron K, Harding NJ, P'ng C, Houlahan KE, Chu KC, Lo B, Nguyen F, Li CH, Sun RX, de Borja R, Cooper CI, Hopkins JF, Govind SK, Fung C, Waggott D, Green J, Haider S, Chan-Seng-Yue MA, Jung E, Wang Z, Bergeron A, Dal Pra A, Lacombe L, Collins CC, Sahinalp C, Lupien M, Fleshner NE, He HH, Fradet Y, Tetu B, van der Kwast T, McPherson JD, Bristow RG, Boutros PC.

Nature. 2017 Jan 19;541(7637):359-364. doi: 10.1038/nature20788. Epub 2017 Jan 9.

PMID:
28068672
32.

Clonality Inference from Single Tumor Samples Using Low-Coverage Sequence Data.

Donmez N, Malikic S, Wyatt AW, Gleave ME, Collins CC, Sahinalp SC.

J Comput Biol. 2017 Jun;24(6):515-523. doi: 10.1089/cmb.2016.0148. Epub 2017 Jan 5.

PMID:
28056180
33.

The Master Neural Transcription Factor BRN2 Is an Androgen Receptor-Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer.

Bishop JL, Thaper D, Vahid S, Davies A, Ketola K, Kuruma H, Jama R, Nip KM, Angeles A, Johnson F, Wyatt AW, Fazli L, Gleave ME, Lin D, Rubin MA, Collins CC, Wang Y, Beltran H, Zoubeidi A.

Cancer Discov. 2017 Jan;7(1):54-71. doi: 10.1158/2159-8290.CD-15-1263. Epub 2016 Oct 26.

34.

BIRC6 Targeting as Potential Therapy for Advanced, Enzalutamide-Resistant Prostate Cancer.

Luk IS, Shrestha R, Xue H, Wang Y, Zhang F, Lin D, Haegert A, Wu R, Dong X, Collins CC, Zoubeidi A, Gleave ME, Gout PW, Wang Y.

Clin Cancer Res. 2017 Mar 15;23(6):1542-1551. doi: 10.1158/1078-0432.CCR-16-0718. Epub 2016 Sep 23.

35.

Framing Young Childrens Oral Health: A Participatory Action Research Project.

Collins CC, Villa-Torres L, Sams LD, Zeldin LP, Divaris K.

PLoS One. 2016 Aug 22;11(8):e0161728. doi: 10.1371/journal.pone.0161728. eCollection 2016.

36.

SiNVICT: ultra-sensitive detection of single nucleotide variants and indels in circulating tumour DNA.

Kockan C, Hach F, Sarrafi I, Bell RH, McConeghy B, Beja K, Haegert A, Wyatt AW, Volik SV, Chi KN, Collins CC, Sahinalp SC.

Bioinformatics. 2017 Jan 1;33(1):26-34. doi: 10.1093/bioinformatics/btw536. Epub 2016 Aug 16.

PMID:
27531099
37.

Non-targeted Metabolomics in Diverse Sorghum Breeding Lines Indicates Primary and Secondary Metabolite Profiles Are Associated with Plant Biomass Accumulation and Photosynthesis.

Turner MF, Heuberger AL, Kirkwood JS, Collins CC, Wolfrum EJ, Broeckling CD, Prenni JE, Jahn CE.

Front Plant Sci. 2016 Jul 11;7:953. doi: 10.3389/fpls.2016.00953. eCollection 2016.

38.

Necroptosis of Dendritic Cells Promotes Activation of γδ T Cells.

Collins CC, Bashant K, Erikson C, Thwe PM, Fortner KA, Wang H, Morita CT, Budd RC.

J Innate Immun. 2016;8(5):479-92. doi: 10.1159/000446498. Epub 2016 Jul 19.

39.

Using the neoadjuvant chemotherapy paradigm to develop precision therapy for muscle-invasive bladder cancer.

Chedgy EC, Douglas J, Wright JL, Seiler R, van Rhijn BW, Boormans J, Todenhöfer T, Dinney CP, Collins CC, Van der Heijden MS, Black PC.

Urol Oncol. 2016 Oct;34(10):469-76. doi: 10.1016/j.urolonc.2016.05.012. Epub 2016 Jun 15. Review.

PMID:
27317490
40.

Transcriptome-Based Analysis of Molecular Pathways for Clusterin Functions in Kidney Cells.

Dairi G, Guan Q, Roshan-Moniri M, Collins CC, Ong CJ, Gleave ME, Nguan CY, Du C.

J Cell Physiol. 2016 Dec;231(12):2628-38. doi: 10.1002/jcp.25415. Epub 2016 Jun 15.

PMID:
27155085
41.

Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer.

Wyatt AW, Azad AA, Volik SV, Annala M, Beja K, McConeghy B, Haegert A, Warner EW, Mo F, Brahmbhatt S, Shukin R, Le Bihan S, Gleave ME, Nykter M, Collins CC, Chi KN.

JAMA Oncol. 2016 Dec 1;2(12):1598-1606. doi: 10.1001/jamaoncol.2016.0494.

42.

The retinoblastoma protein regulates hypoxia-inducible genetic programs, tumor cell invasiveness and neuroendocrine differentiation in prostate cancer cells.

Labrecque MP, Takhar MK, Nason R, Santacruz S, Tam KJ, Massah S, Haegert A, Bell RH, Altamirano-Dimas M, Collins CC, Lee FJ, Prefontaine GG, Cox ME, Beischlag TV.

Oncotarget. 2016 Apr 26;7(17):24284-302. doi: 10.18632/oncotarget.8301.

43.

Identification of the epigenetic reader CBX2 as a potential drug target in advanced prostate cancer.

Clermont PL, Crea F, Chiang YT, Lin D, Zhang A, Wang JZ, Parolia A, Wu R, Xue H, Wang Y, Ding J, Thu KL, Lam WL, Shah SP, Collins CC, Wang Y, Helgason CD.

Clin Epigenetics. 2016 Feb 12;8:16. doi: 10.1186/s13148-016-0182-9. eCollection 2016.

44.

Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients.

Lallous N, Volik SV, Awrey S, Leblanc E, Tse R, Murillo J, Singh K, Azad AA, Wyatt AW, LeBihan S, Chi KN, Gleave ME, Rennie PS, Collins CC, Cherkasov A.

Genome Biol. 2016 Jan 26;17:10. doi: 10.1186/s13059-015-0864-1.

45.

The MCT4 Gene: A Novel, Potential Target for Therapy of Advanced Prostate Cancer.

Choi SY, Xue H, Wu R, Fazli L, Lin D, Collins CC, Gleave ME, Gout PW, Wang Y.

Clin Cancer Res. 2016 Jun 1;22(11):2721-33. doi: 10.1158/1078-0432.CCR-15-1624. Epub 2016 Jan 11.

46.

The Proteome of Primary Prostate Cancer.

Iglesias-Gato D, Wikström P, Tyanova S, Lavallee C, Thysell E, Carlsson J, Hägglöf C, Cox J, Andrén O, Stattin P, Egevad L, Widmark A, Bjartell A, Collins CC, Bergh A, Geiger T, Mann M, Flores-Morales A.

Eur Urol. 2016 May;69(5):942-52. doi: 10.1016/j.eururo.2015.10.053. Epub 2015 Dec 2.

PMID:
26651926
47.

The Placental Gene PEG10 Promotes Progression of Neuroendocrine Prostate Cancer.

Akamatsu S, Wyatt AW, Lin D, Lysakowski S, Zhang F, Kim S, Tse C, Wang K, Mo F, Haegert A, Brahmbhatt S, Bell R, Adomat H, Kawai Y, Xue H, Dong X, Fazli L, Tsai H, Lotan TL, Kossai M, Mosquera JM, Rubin MA, Beltran H, Zoubeidi A, Wang Y, Gleave ME, Collins CC.

Cell Rep. 2015 Aug 11;12(6):922-36. doi: 10.1016/j.celrep.2015.07.012. Epub 2015 Jul 30.

48.

Spatial genomic heterogeneity within localized, multifocal prostate cancer.

Boutros PC, Fraser M, Harding NJ, de Borja R, Trudel D, Lalonde E, Meng A, Hennings-Yeomans PH, McPherson A, Sabelnykova VY, Zia A, Fox NS, Livingstone J, Shiah YJ, Wang J, Beck TA, Have CL, Chong T, Sam M, Johns J, Timms L, Buchner N, Wong A, Watson JD, Simmons TT, P'ng C, Zafarana G, Nguyen F, Luo X, Chu KC, Prokopec SD, Sykes J, Dal Pra A, Berlin A, Brown A, Chan-Seng-Yue MA, Yousif F, Denroche RE, Chong LC, Chen GM, Jung E, Fung C, Starmans MH, Chen H, Govind SK, Hawley J, D'Costa A, Pintilie M, Waggott D, Hach F, Lambin P, Muthuswamy LB, Cooper C, Eeles R, Neal D, Tetu B, Sahinalp C, Stein LD, Fleshner N, Shah SP, Collins CC, Hudson TJ, McPherson JD, van der Kwast T, Bristow RG.

Nat Genet. 2015 Jul;47(7):736-45. doi: 10.1038/ng.3315. Epub 2015 May 25.

PMID:
26005866
49.

Polycomb-mediated silencing in neuroendocrine prostate cancer.

Clermont PL, Lin D, Crea F, Wu R, Xue H, Wang Y, Thu KL, Lam WL, Collins CC, Wang Y, Helgason CD.

Clin Epigenetics. 2015 Apr 3;7:40. doi: 10.1186/s13148-015-0074-4. eCollection 2015.

50.

The epigenetic/noncoding origin of tumor dormancy.

Crea F, Nur Saidy NR, Collins CC, Wang Y.

Trends Mol Med. 2015 Apr;21(4):206-11. doi: 10.1016/j.molmed.2015.02.005. Epub 2015 Mar 11.

PMID:
25771096

Supplemental Content

Loading ...
Support Center